» Articles » PMID: 10910013

Norepinephrine Dysfunction in Depression

Overview
Specialty Psychiatry
Date 2000 Jul 26
PMID 10910013
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

The study of the noradrenergic neurotransmitter system remains one of the cornerstones of depression research. Better understanding of the action of norepinephrine and other catecholamines at the synaptic and intracellular level holds the potential for providing clues to the etiology of depression and introduces exciting possibilities for the development of novel medications for the treatment of depression. The following review of norepinephrine as it relates to depression will shed light on the current understanding of the noradrenergic system and the role for selective norepinephrine reuptake inhibitors (selective NRIs) in the treatment of depression.

Citing Articles

a Possible Treatment for Depressive Disorders.

Mata-Bermudez A, Diaz-Ruiz A, Silva-Garcia L, Gines-Francisco E, Noriega-Navarro R, Rios C Neurol Int. 2024; 16(6):1509-1527.

PMID: 39585071 PMC: 11587415. DOI: 10.3390/neurolint16060112.


Clinical value and mechanistic analysis of HIIT on modulating risk and symptoms of depression: A systematic review.

Xu Y, Li Y, Wang C, Han T, Wu Y, Wang S Int J Clin Health Psychol. 2024; 24(1):100433.

PMID: 38226005 PMC: 10788816. DOI: 10.1016/j.ijchp.2023.100433.


The role of neurotrophic factors in novel, rapid psychiatric treatments.

Kim J, He M, Widmann A, Lee F Neuropsychopharmacology. 2023; 49(1):227-245.

PMID: 37673965 PMC: 10700398. DOI: 10.1038/s41386-023-01717-x.


Depression and Parkinson's disease: a Chicken-Egg story.

Chakraborty A, Diwan A AIMS Neurosci. 2023; 9(4):479-490.

PMID: 36660077 PMC: 9826748. DOI: 10.3934/Neuroscience.2022027.


Saliva tau and phospho-tau-181 measured by Lumipulse in patients with Alzheimer's disease.

Marksteiner J, Defrancesco M, Humpel C Front Aging Neurosci. 2022; 14:1014305.

PMID: 36247998 PMC: 9557075. DOI: 10.3389/fnagi.2022.1014305.